SFA Therapeutics novel immunomodualtor, SFA006 is planned for testing in COVID-19 Patients 4th Quarter 2020
The trial will test the compound’s ability to prevent the onset of Cytokine Storm Syndrome (CSS) and progression to Acute Respiratory Distress Syndrome (ARDS) in COVID-19 positive patients.
Patients will be dosed and monitored for symptom progression hospitalization and death
SFA006 to be tested in patients suffering from Post-COVID Syndrome
The trial will test the compound’s affect on COVID-19 patients’ symtomology after COVID-19 clearance who continue to suffer from lingering long term effects of COVID-19, so-called Post-Covid Syndrome “Long Haulers”